

Clinical Trial Protocol

Iranian Registry of Clinical Trials

11 Sep 2026

Evaluating the effect of Myrobalan (Terminalia Chebula.) cream, 5% compared to hydroquinone cream, 2% in the treatment of melasma

Protocol summary

Study aim

Evaluating the Effectiveness of 5% Terminalia Chebula Retz. In Melasma Treatment

Design

This study is a randomized, double-blind clinical trial with a parallel group design of 48 patients

Settings and conduct

Patients are selected from Afzalipour Hospital of Kerman. Participants and physicians are blinded. The patients are assessed at baseline and after 4 and 8 and 12 weeks of using each cream based on Modified Melasma Area and Severity Index.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Women in the 18-55 age range with melasma Exclusion criteria: Pregnancy, lactation, antiepileptic drugs and spironolactone Thyroid disorders, polycystic ovary syndrome, anti-smear drug use during last 6 months, Use of oral and phototoxic contraceptives since last month, sensitivity to hydroquinone or Terminalia Chebula

Intervention groups

The treatment group use 5% cream containing the extract of Cable Harleys once in the night and the control group use 2% Hydroquinone

Main outcome variables

Modified Melasma Area and Severity Index (MMASI)

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20110310006026N10**

Registration date: **2019-09-29, 1398/07/07**

Registration timing: **registered_while_recruiting**

Last update: **2019-09-29, 1398/07/07**

Update count: **0**

Registration date

2019-09-29, 1398/07/07

Registrant information

Name

Fatemeh Dabaghzadeh

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 34 3132 5034

Email address

dabaghzadeh@razi.tums.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2019-09-22, 1398/06/31

Expected recruitment end date

2020-01-19, 1398/10/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluating the effect of Myrobalan (Terminalia Chebula.) cream, 5% compared to hydroquinone cream, 2% in the treatment of melasma

Public title

"Effect of Terminalia Chebula in treatment of melasma"

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Women in the 18-55 age range with melasma

Exclusion criteria:

Pregnancy, lactation, antiepileptic drugs and spironolactone Thyroid disorders, polycystic ovary syndrome, anti-smear drug use during last 6 months, Use of oral and phototoxic contraceptives since last month, sensitivity to hydroquinone or Terminalia Chebula

Age

From **18 years** old to **55 years** old

Gender

Both

Phase

1-2

Groups that have been masked

- Participant

Sample size

Target sample size: **48**

Randomization (investigator's opinion)

Randomized

Randomization description

The eligible participants are allocated to one of the two study groups in a 1:1 ratio. Allocation is by block randomization with a block size of four. A person (not involved in the trial) generates allocation sequence

Blinding (investigator's opinion)

Double blinded

Blinding description

Participants and physician: The packaging of hydroquinone and Terminalia Chebula are similar in color and shape.

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of Kerman University of Medical Sciences

Street address

Beginning of Jahad Blvd., Tahmasebad Fourways

City

Kerman

Province

Kerman

Postal code

7619813159

Approval date

2019-08-24, 1398/06/02

Ethics committee reference number

IR.KMU.REC.1398.254

Health conditions studied

1

Description of health condition studied

Melasma

ICD-10 code

L81.1

ICD-10 code description

Chloasma

Primary outcomes

1

Description

Melanin

Timepoint

At the beginning of treatment and at the end of weeks 4, 8 and 12

Method of measurement

Modified Melasma Area and Severity Index (MMASI)

Secondary outcomes

empty

Intervention groups

1

Description

Intervention group: 5% myrobalan cream which rub a thin layer of medicine every night and wash face in the morning.

Category

Treatment - Drugs

2

Description

Control group: 2% hydroquinone cream which rub a thin layer of medicine every night and wash face in the morning.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Afzali Pour hospital of Kerman

Full name of responsible person

Fatemeh Dabaghzadeh

Street address

Haft bagh high way

City

Kerman

Province

Kerman

Postal code
7616913555
Phone
+98 34 3132 5212
Email
fatemeh.dabaghzadeh@gmail.com

Sponsors / Funding sources

1

Sponsor

Name of organization / entity
Kerman University of Medical Sciences
Full name of responsible person
Abbas Pardakhty
Street address
Beginning of Jihad Blvd., Tahmasebad Fourways
City
Kerman
Province
Kerman
Postal code
7619813159
Phone
+98 34 3226 3815
Email
abpardakhty@kmu.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
Yes
Title of funding source
Kerman University of Medical Sciences
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact

Name of organization / entity
Kerman University of Medical Sciences
Full name of responsible person
Fatemeh Dabaghzadeh
Position
Assistant professor
Latest degree
Ph.D.
Other areas of specialty/work
Clinical pharmacy
Street address
Faculty of Pharmacy, Kerman University of Medical

Sciences , Haft Bagh ave, Kerman, Iran
City
Kerman
Province
Kerman
Postal code
7616913555
Phone
+98 34 3132 5034
Fax
+98 34 3132 5003
Email
fatemeh.dabaghzadeh@gmail.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Kerman University of Medical Sciences
Full name of responsible person
Fatemeh Dabaghzadeh
Position
Assistant professor
Latest degree
Ph.D.
Other areas of specialty/work
Clinical Pharmacy
Street address
Faculty of Pharmacy, Kerman University of Medical Sciences , Haft Bagh ave, Kerman, Iran
City
Kerman
Province
Kerman
Postal code
7616913555
Phone
+98 34 3132 5034
Fax
+98 34 3132 5003
Email
fatemeh.dabaghzadeh@gmail.com

Person responsible for updating data

Contact

Name of organization / entity
Kerman University of Medical Sciences
Full name of responsible person
Fatemeh Dabaghzadeh
Position
Assistant professor
Latest degree
Ph.D.
Other areas of specialty/work
Clinical Pharmacy
Street address
Faculty of Pharmacy, Kerman University of Medical Sciences , Haft Bagh ave, Kerman, Iran
City
Kerman

Province

Kerman

Postal code

7616913555

Phone

+98 34 3132 5034

Fax

+98 34 3132 5003

Email

fatemeh.dabaghzadeh@gmail.com

Sharing plan**Deidentified Individual Participant Data Set (IPD)**

No - There is not a plan to make this available

Justification/reason for indecision/not sharing IPD

There is no further information

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available